A cytogenetic and haematological investigation of oil exposed workers in a Norwegian cable manufacturing company

Autor: A Rønneberg, O Jelmert, K Skyberg, I L Hansteen

Publikováno v: Occupational and Environmental Medicine. 46:791-798

Cytogenetic and haematological parameters were studied in 31 oil exposed workers and 31 office workers matched for age and smoking, all men employed by a Norwegian cable manufacturing company. Information was obtained about tobacco and alcohol consum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::221246c19b0751f6499a554ad22ff369
https://doi.org/10.1136/oem.46.11.791

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial.

Autor: Pollard RB; Division of Infectious Diseases, UC Davis Medical Center, Sacramento, CA, USA., Rockstroh JK; Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I, Immunologische Ambulanz, Bonn, Germany., Pantaleo G; Division of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland., Asmuth DM; Division of Infectious Diseases, UC Davis Medical Center, Sacramento, CA, USA., Peters B; Harrison Wing, St Thomas' Hospital, London, UK., Lazzarin A; Department of Infectious Diseases, Ospedale San Raffaele and Vita-Salute University, Milan, Italy., Garcia F; Infectious Diseases and AIDS Units, Hospital Clinic/IDIBAPS, University of Barcelona, Barcelona, Spain., Ellefsen K; Division of Immunology and Allergy, Lausanne University Hospital, Lausanne, Switzerland., Podzamczer D; HIV Unit, Infectious Disease Service, Hospital Universitari de Bellvitge, Barcelona, Spain., van Lunzen J; Universitätsklinikum Hamburg Eppendorf, Ambulanzzentrum Infektiologie, Hamburg, Germany., Arastéh K; EPIMED-Gesellschaft für Epidemiologische und Klinische Forschung in der Medizin mbH/Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany., Schürmann D; Department of Internal Medicine, Division of Infectious Diseases and Pulmonary Medicine, Charité-University Medicine Berlin, Berlin, Germany., Clotet B; Irsicaixa Foundation, UAB, UVic, Hospital Universitari 'Germans Trias i Pujol', Badalona, Catalonia, Spain., Hardy WD; Division of Infectious Diseases Cedars-Sinai Medical Center, Los Angeles, CA, USA., Mitsuyasu R; UCLA CARE Center, University of California, Los Angeles, CA, USA., Moyle G; Kobler Clinic, Chelsea and Westminster Hospital, London, UK., Plettenberg A; ifi-Institut, an der Asklepios-Klinik St Georg, Hamburg, Germany., Fisher M; Brighton and Sussex University Hospital, HIV/GUM Research, Elton John Centre, Brighton, UK., Fätkenheuer G; Klinik I für Innere Medizin, Klinikum der Universität zu Köln, Cologne, Germany., Fischl M; University of Miami School of Medicine AIDS Clinical Research Unit, Miami, FL, USA., Taiwo B; Division of Infectious Diseases, Northwestern University, Chicago, IL, USA., Baksaas I; Mericon AS, Skien, Norway., Jolliffe D; Aptiv Solutions, Abingdon, UK., Persson S; SP PharmaConsulting, Uppsala, Sweden., Jelmert O; Bionor Laboratories, Skien, Norway., Hovden AO; Bionor Pharma ASA, Oslo, Norway., Sommerfelt MA; Bionor Pharma ASA, Oslo, Norway., Wendel-Hansen V; Bionor Pharma ASA, Oslo, Norway. Electronic address: post@bionorpharma.com., Sørensen B; Bionor Pharma ASA, Oslo, Norway.

Publikováno v: The Lancet. Infectious diseases [Lancet Infect Dis] 2014 Apr; Vol. 14 (4), pp. 291-300. Date of Electronic Publication: 2014 Feb 11.